SGIOY News and Press, Shionogi & Co. Ltd. ADR From 10/12/19

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

A Phase 3 clinical trial, ATLAS-2M , evaluating the combination of ViiV Healthcare's cabotegravir and Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals' rilpivirine administered every two months showed it to be non-inferior (no worse than) to monthly dosing in adult patients...

ViiV Healthcare has filed a marketing application in Europe seeking approval for the combination of cabotegravir and Johnson & Johnson ( JNJ -0.2% ) unit Janssen Therapeutics' rilpivirine, administered via monthly injection, for the treatment of HIV-1 infection in adults with suppres...

Results from a Phase 3 clinical trial, BRIGHTE , evaluating ViiV Healthcare's fostemsavir in heavily pretreated HIV patients showed a treatment benefit. The data were presented at the International AIDS Society Conference on HIV Science in Mexico City. More news on: GlaxoSmithKlin...

Noteworthy events during the week of July 21 - 27 for healthcare investors. More news on: Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Healthcare stocks news, , Read more ...

ViiV Healthcare announces positive results from a Phase 3 clinical trial, TANGO , evaluating its two-drug HIV regimen of dolutegravir + lamivudine in virally suppressed patients switching from a TAF-containing three-drug regimen. More news on: GlaxoSmithKline plc, Pfizer Inc., Shionogi ...

ViiV Healthcare commences a U.S.-based study, CUSTOMIZE, aimed at identifying and assessing the best ways to implement a once-monthly injectable treatment for HIV infection into clinical practice. The goal is to find the most practical and efficient ways to manage monthly treatment. More...

Results from a Phase 3 clinical trial, MINISTONE-2 , evaluating an oral suspension formulation of Roche ( OTCQX:RHHBY ) unit Genentech's XOFLUZA (baloxavir marboxil) in children with the flu showed that it was well-tolerated and reduced the duration of flu symptoms. More news on: Roche...

Roche ( OTCQX:RHHBY ) unit Genentech announces the successful outcome of a Japan-based Phase 3 clinical trial, BLOCKSTONE, evaluating the effect of XOFLUZA (baloxavir marboxil) on preventing influenza infection. More news on: Roche Holding AG, Shionogi & Co., Ltd., Healthcare stocks ...

Matinas BioPharma ( MTNB -0.3% ) inks a research collaboration agreement with ViiV Healthcare under which the latter will explore the use of the former's lipid nano-crystal (LNC) platform delivery technology in developing new antivirals. More news on: Matinas BioPharma Holdings, Inc....